International Flavors & Fragrances(IFF) - 2025 Q4 - Annual Results

Financial Performance - Reported net sales for the full year 2025 were $10.89 billion, a decrease of 5% compared to the prior year, while currency neutral sales increased by 2%[4] - The loss before taxes for the full year was $412 million, and the reported EPS was $(1.46), while adjusted EPS excluding amortization was $4.20[2][7] - For the fourth quarter, reported net sales were $2.59 billion, a decrease of 7% year-over-year, but currency neutral sales increased by 1%[12] - Net sales for Q4 2025 were $2,589 million, a decrease of 7% compared to Q4 2024's $2,771 million, and full-year sales were $10,890 million, down 5% from $11,484 million in 2024[39] - The company reported a net loss of $412 million for 2025, compared to a net income of $308 million in 2024, indicating a significant shift in financial performance[73] EBITDA and Profitability - Adjusted operating EBITDA for the full year was $2.086 billion, with a currency neutral increase of 7% driven by volume growth and productivity gains[4] - The fourth quarter adjusted operating EBITDA was $437 million, with a comparable currency neutral increase of 7% primarily due to productivity gains[12] - Adjusted Operating EBITDA for the twelve months ended December 31, 2025, was $2,086 million, compared to $2,200 million in the previous year, reflecting a decrease of 5.2%[49] - The consolidated Adjusted Operating EBITDA margin for the twelve months ended December 31, 2025, was 19.2%, down from 19.5% in the previous year[49] - Segment Adjusted Operating EBITDA margin for the consolidated results improved to 19.2% in 2025 from 18.7% in 2024[88] Cash Flow and Debt - Cash flow from operations for the full year was $850 million, with free cash flow totaling $256 million[7] - Total debt to trailing twelve months net income at the end of Q4 was 16.2x, while net debt to credit-adjusted EBITDA was 2.6x[7] - The company reported a net cash provided by operating activities of $850 million for 2025, down from $1,070 million in 2024[43] - The company’s long-term debt decreased to $4,740 million in 2025 from $7,564 million in 2024, reflecting a reduction in leverage[41] - Total debt as of December 31, 2025, was $6,026 million, with net debt calculated at $5,436 million after accounting for cash and cash equivalents of $590 million[83] Research and Development - Research and development expenses increased by 2% in Q4 2025 to $174 million, and for the full year, they rose by 3% to $694 million compared to $671 million in 2024[39] - Research and development expenses for the three months ended December 31, 2025, were $175 million, compared to $168 million in the same period of 2024, indicating an increase of 4.2%[46][47] - Research and development expenses totaled $1.071 billion, reflecting a focus on innovation across segments[50] Strategic Initiatives and Divestitures - The company is in the process of divesting its Food Ingredients segment to sharpen strategic focus and improve financial flexibility[3] - The company incurred restructuring and other charges of $70 million for the full year 2025, a significant increase of 141% compared to $29 million in 2024[39] - Business divestiture costs were approximately $35 million in Q4 2025, down from $56 million in Q4 2024, indicating improved cost management[62] - The company is undergoing a phased restructuring initiative aimed at optimizing its legal entity framework, which includes costs related to entity realignment[51] - Business divestiture costs for 2025 were approximately $125 million, while costs for 2024 were around $220 million, indicating a reduction in divestiture-related expenses[76] Segment Performance - The Taste segment reported sales of $588 million in Q4 2025, a 2.6% increase from $573 million in Q4 2024, with an operating EBITDA margin of 16.0%[88] - Health & Biosciences segment sales increased to $589 million in Q4 2025, compared to $550 million in Q4 2024, with an operating EBITDA margin of 26.3%[88] - The Scent segment achieved sales of $610 million in Q4 2025, up from $578 million in Q4 2024, with an operating EBITDA margin of 17.4%[88] - The Pharma Solutions segment reported a significant decline in sales, down 65% year-over-year, reflecting the impact of divestitures[96] Future Outlook - The company expects full year 2026 sales to be in the range of $10.5 billion to $10.8 billion, with adjusted operating EBITDA projected between $2.05 billion and $2.15 billion[14] - Comparable currency neutral sales growth for 2026 is expected to be between 1% to 4%, with adjusted operating EBITDA growth anticipated to be 3% to 8% year-over-year[15] - Future outlook includes continued investment in strategic initiatives and productivity programs to enhance operational efficiency[51] - The company anticipates continued growth in the Taste and Health & Biosciences segments, driven by new product innovations and market expansion strategies[88]